Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Lipocine Reports Positive Clinical Results for Novel Once-A-Day Oral Testosterone

Published: Tuesday, April 09, 2013
Last Updated: Tuesday, April 09, 2013
Bookmark and Share
LPCN 1111, a novel prodrug of testosterone, uses the Company’s proprietary Lip’ral technology to enhance solubility and improve absorption during testosterone replacement therapy.

Data from the Phase I study established that LPCN 1111 exhibited a strong safety profile and pharmacokinetics which should allow for once-a-day dosing of this next-generation oral testosterone replacement product. The LPCN 1111 development program complements Lipocine’s robust pipeline of potential products including LPCN 1021, a twice-daily oral testosterone replacement, currently entering Phase III clinical trials.

“We are very pleased to report that data from the Phase I trial indicate that LPCN 1111 appears to be the first once-a-day, orally-active testosterone replacement therapy ever advanced into the clinic. This is an important step in the development of this potentially groundbreaking therapy,” said Dr. Srinivasan Venkateshwaran, Chief Technology Officer of Lipocine Inc.

“New oral testosterone dosage forms will make a major contribution to the expanding market for testosterone replacement therapy, an established and safe way to treat testosterone deficiency. We believe a once-a-day product will be strongly differentiated and provide a significant advancement in this market. Based on these data, LPCN 1111 is poised to be the first such product in this class,” added Dr. Mahesh Patel, President and CEO of Lipocine Inc.

Testosterone Replacement Therapy (TRT) is an underserved and rapidly expanding segment of health care for men. An independent study in the US indicates that the majority of symptomatic men are not being treated for low testosterone, due in part to the insufficient treatment options currently available. Topical gels currently account for almost 90% of testosterone sales, but carry a boxed warning from the FDA due to concerns about transfer of the gel, and therefore the hormone, to women and infants during use. Lipocine has designed orally available LPCN 1111 specifically to address these issues and provide a safe, effective and convenient therapeutic option.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Uncovering How Some Breast Cancers Resist Treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Activating Cancer-Killing Immune Cells
A UCL research team have discovered that cutting off a sleep-switch on immune cells inside a tumour wakes up the cells and enables the immune system to hunt down and destroy cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!